Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
20.65
+0.18 (0.88%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.

In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.

It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.

Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S
Genmab logo
Country Denmark
Founded 1999
Industry Biotechnology
Sector Healthcare
Employees 2,204
CEO Jan G.J. de Winkel

Contact Details

Address:
Carl Jacobsens Vej 30, Valby
Copenhagen, 2500
Denmark
Phone 45 70 20 27 28
Website genmab.com

Stock Details

Ticker Symbol GMAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency DKK
CIK Code 0001434265
CUSIP Number 372303206
ISIN Number US3723032062
SIC Code 2834

Key Executives

Name Position
Dr. Jan G.J. van de Winkel Ph.D. Co-Founder, President and Chief Executive Officer
Birgitte Stephensen M.Sc. Executive Vice President and Chief Legal Officer
Christopher Cozic Executive Vice President and Chief People Officer
Dr. Martine J. van Vugt Ph.D. Executive Vice President and Chief Strategy Officer
Martin Schultz Senior Director of Clinical Operations and Non-Independent Director
Dr. Judith V. Klimovsky M.D. Executive Vice President and Chief Development Officer
Dr. Tahamtan Ahmadi Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
Dr. Mijke Zachariasse Ph.D. Senior Director, Head of Antibody Research Materials and Non-Independent Director
Takahiro Hamatani Senior Director of Finance Japan and Non-Independent Director
Rayne Waller Executive Vice President and Chief Technology Officer

Latest SEC Filings

Date Type Title
Nov 21, 2024 6-K Report of foreign issuer
Nov 6, 2024 6-K Report of foreign issuer
Oct 15, 2024 6-K Report of foreign issuer
Oct 4, 2024 6-K Report of foreign issuer
Oct 1, 2024 6-K Report of foreign issuer
Sep 26, 2024 6-K Report of foreign issuer
Sep 11, 2024 6-K Report of foreign issuer
Sep 10, 2024 6-K Report of foreign issuer
Aug 21, 2024 6-K Report of foreign issuer
Aug 14, 2024 6-K Report of foreign issuer